Pipeline

Our most advanced pipeline programs are varegacestat (formerly AL102), a late-clinical stage gamma secretase inhibitor for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which received IND clearance in Q1 2025. Our preclinical pipeline includes IM-1617, IM-1340, and IM-1335, all of which are ADCs pursuing undisclosed targets with expression in multiple solid tumors.